Study Design

INA-PROACTIVE is a multicenter, prospective, observational cohort study of HIV positive antiretroviral-naĂŻve and treatment-experienced individuals. No investigational treatment or intervention will be used by this study. All participants will be managed according to the Indonesian HIV/AIDS Treatment Guideline and the Standard of Care (SoC) in local clinical setting, with the addition of rapid HIV viral load, CD4 cell count and syphilis testing.

Data will be collected on all participants at baseline and follow up visits every 6 months (±3-month window period). Additional follow up data may be collected on selected participants who meet additional study follow up criteria.

Subject Characteristics

In this report, the focus is on analyzing pediatric patients. Initially, there were 189 pediatric patients under consideration. However, after careful evaluation, six pediatric patients were excluded from the analysis. These exclusions were based on the presence of certain risk factors associated with acquiring HIV, including engaging in heterosexual or homosexual behaviors, being recipients of blood products, or lacking documentation of LOG 700. These criteria were applied to ensure a more homogeneous study population for accurate analysis and interpretation of the data.

Those patients are:
ID_patients Reason
1045601008 Blood product recipient
1045701004 Homosexual
1046301006 Homosexual
1046801001 Heterosexual
1046901004 Heterosexual
1046701001 Does not have LOG 700

Subject Characteristics (All)

In this section, table characteristics is shown for subject characteristics at Enrollment PROACTIVE study.

deskriptif <- read_excel("table_deskriptif.xlsx", na = "-")
options(knitr.kable.NA = '')
deskriptif %>%
  kbl() %>%
  kable_classic_2(full_width = F)
Characteristics Subject (N = 189)
Age (months), median (IQR) 95.0 (63.0 - 147.0)
Gender
Male 90 (47.6%)
Female 99 (52.4%)
Risk factors for acquiring HIV
Heteroseksual 2 (1.1%)
Homoseksual 2 (1.1%)
Perinatal 175 (92.6%)
Suspected perinatal 9 (4.8%)
Transplant recipient 1 (0.5%)
Smoking and Alcohol
Ever smoke 3 (1.6%)
Ever consume alcohol 1 (0.5%)
Family Medical History
HIV-Spouse 1 (53.8%)
HIV-Father 110 (59,1%)
HIV-Mother 173 (93.0%)
HIV-Child 0 (0.0%)
HIV-Sibling 19 (10.2%)
HIV-From Household 1 (0.5%)
HIV-Others 0 (0.0%)
TB-Spouse 0 (0.0%)
TB-Father 38 (24.0%)
TB-Mother 34 (21.5%)
TB-Child 0 (0.0%)
TB-Sibling 8 (5.0%)
TB-From Household 8 (5.0%)
TB-Others 0 (0.0%)
Hepatitis B-Spouse 0 (0.0%)
Hepatitis B-Father 3 (2.1%)
Hepatitis B-Mother 3 (2.1%)
Hepatitis B-Child 0 (0.0%)
Hepatitis B-Sibling 0 (0.0%)
Hepatitis B-From Household 1 (0.7%)
Hepatitis B-Others 0 (0.0%)
Hepatitis C-Spouse 0 (0.0%)
Hepatitis C-Father 6 (4,2%)
Hepatitis C-Mother 1 (0.7%)
Hepatitis C-Child 0 (0.0%)
Hepatitis C-Sibling 0 (0.0%)
Hepatitis C-From Household 0 (0.0%)
Hepatitis C-Others 0 (0.0%)
HIV Testing History
Ever tested HIV 1 (0.5%)
Own Initiative tested 11 (5.8%)
Provider Initiated 171 (90.5%)
Others 7 (3.7%)
CD4 and Viral Load
CD4 at baseline 481.0 (159.5 - 981.5)
Latest viral load 56 (1 - 46000)
Highest viral load 87200 (144 - 712000)
Pulmonary and extra-pulmonary tuberculosis prior to and at enrollment
Pulmonary 71 (37.5%)
Others 106 (56.1%)
Extra-Pulmonary 12 (6.4%)
Limfadenitis 2 (3.7%)
Pleural effusion 3 (1.1%)
Bone TB 5 (0.5%)
Other (TB Milier, Skin) 2 (1.1%)
Delivery methods (vaginam, elective and non-elective SC)
Vaginam 133 (70.4%)
Elective Caesarean Section 22 (11.6%)
Non-elective Caesarean Section 17 (8.9%)
Others 9 (4.7%)
Birth history
Birth weight (gram) 3000 (2800 - 3500)
Birth defects 1 (0.5%)
ARV during pregnancy 2 (1.1%)
Child receive ARV 69 (36.5%)
Exclusive breastfeeding 134 (70.9%)
Neonatal status
Full-term 165 (87.3%)
Pre-term 7 (3.7)
Vital Signs
Weight 13.1 (8.7 - 19.7)
Height 20.1 (22.4 - 16.5)
Waist circumference 55.0 (50.0 - 60.0)
Syphilis result 70 (37.0%)

Subject Characteristics (Alive and LTFU)

deskriptif2 <- read_excel("table_clinical.xlsx")
options(knitr.kable.NA = '')
deskriptif2 %>%
  kbl() %>%
  kable_classic_2(full_width = F)
Group ARV Group (N,%) P-value
Alive NaĂŻve 7 (4.5%) 0.5664
< 6 months 12 (7.7%)
6 - 12 months 10 (6.5%)
> 12 months 126 (81.3%)
LTFU NaĂŻve 1 (5.9%) 0.416
< 6 months 0 (0.0%)
6 - 12 months 0 (0.0%)
> 12 months 16 (94.1%)

Plots

Plot Naive, Experience Group

  • The “Naive group” includes individuals who have never undergone ART treatment.
  • The “Experience group” consists of those who have received ART treatment for at least one day.
  • Enrollment date serves as the baseline for counting the duration until the first ARV treatment for individuals in both groups.
Naive_experience <- read_excel("Naive_experience.xlsx")

ggplot(Naive_experience, aes(x=Var1, y=Freq, fill=Var1)) + 
  geom_bar(stat = "identity") + 
  theme_minimal() +
  ggtitle("Naive, Experience Group") +
  xlab("Groups") +
  scale_x_discrete(labels=c("0" = "Naive", "1" = "<6 months",
                            "2" = "6-12 months", "3"=">12months")) +
  geom_text(aes(label = Freq), vjust = -0.3, size = 3.5) +
  scale_fill_manual(name = "", labels = c("Naive", "<6 months", "6-12 months",">12months"),
                    values = c("#22A884FF","#7AD151FF","#FDE725FF", "#440154FF"))

Plot Alive and LTFU Vs Age Groups

  • The “LTFU” group comprises individuals who were lost to follow up during the study period.
  • The “Alive” group consists of individuals who survived until the end of the study.
  • The “Others” group includes individuals who either withdrew from the study or died during the study period.
## Warning: Removed 4 rows containing missing values (`position_stack()`).
## Removed 4 rows containing missing values (`position_stack()`).

Survival Analysis

Survival Analysis Duration ART Treatment

Survival analysis was conducted among individuals categorized into four groups based on the duration of antiretroviral therapy (ART) treatment: naive, <6 months, 6 to 12 months, and >12 months.

fit1 <- survfit(surv_object ~ Categories, data = Surv_ENR)
summary(fit1)
## Call: survfit(formula = surv_object ~ Categories, data = Surv_ENR)
## 
##                 Categories=1 
##      time n.risk n.event survival std.err lower 95% CI upper 95% CI
## 
##                 Categories=2 
##         time       n.risk      n.event     survival      std.err lower 95% CI 
##     819.0000      13.0000       1.0000       0.9231       0.0739       0.7890 
## upper 95% CI 
##       1.0000 
## 
##                 Categories=3 
##      time n.risk n.event survival std.err lower 95% CI upper 95% CI
## 
##                 Categories=4 
##  time n.risk n.event survival std.err lower 95% CI upper 95% CI
##    43    151       1    0.993  0.0066        0.981        1.000
##   274    150       1    0.987  0.0093        0.969        1.000
##   383    149       1    0.980  0.0114        0.958        1.000
##   392    148       1    0.974  0.0131        0.948        0.999
##   518    146       1    0.967  0.0146        0.939        0.996
##   552    145       1    0.960  0.0159        0.929        0.992
##   567    144       1    0.954  0.0172        0.920        0.988
##   708    143       1    0.947  0.0183        0.912        0.983
ggsurvplot(fit1, data = Surv_ENR, pval = TRUE)

By convention, vertical lines indicate censored data, their corresponding x values the time at which censoring occurred.

The log-rank p-value of 0.77 indicates a non-significant result if consider p < 0.05 to indicate statistical significance. In this study, none of the duration of ART treatment were significantly superior, although Categories 1(Naive) and Categories 3(6-12 months) are doing better until end of study.

Survival Analysis Sex

Surv_ENR$SEX_E1_C2 <- factor(Surv_ENR$SEX_E1_C2 , 
                     levels = c("1", "2"), 
                     labels = c("Male", "Female"))
fit2 <- survfit(surv_object ~ SEX_E1_C2, data = Surv_ENR)
summary(fit2)
## Call: survfit(formula = surv_object ~ SEX_E1_C2, data = Surv_ENR)
## 
##                 SEX_E1_C2=Male 
##  time n.risk n.event survival std.err lower 95% CI upper 95% CI
##   383     87       1    0.989  0.0114        0.966        1.000
##   392     86       1    0.977  0.0161        0.946        1.000
##   518     84       1    0.965  0.0196        0.928        1.000
##   552     83       1    0.954  0.0226        0.910        0.999
##   708     82       1    0.942  0.0251        0.894        0.993
## 
##                 SEX_E1_C2=Female 
##  time n.risk n.event survival std.err lower 95% CI upper 95% CI
##    43     96       1    0.990  0.0104        0.969        1.000
##   274     94       1    0.979  0.0147        0.951        1.000
##   567     93       1    0.969  0.0179        0.934        1.000
##   819     92       1    0.958  0.0206        0.919        0.999
ggsurvplot(fit2, data = Surv_ENR, pval = TRUE)

Similar to the previous plot, which did not indicate statistical significance, the current plot also shows a non-significant log-rank p-value of 0.63. This suggests that there are no significant differences in survival between males and females in this study.

Hazard Ratio Group of Categories and Sex

# Fit a Cox proportional hazards model
fit.coxph <- coxph(surv_object ~ Categories + SEX_E1_C2, 
                   data = Surv_ENR)
ggforest(fit.coxph, data = Surv_ENR)

Hazard ratio of 0.73 for sex groups tells that female patients have a reduced risk of dying compared to male patients (which served as a reference to calculate the hazard ratio). Using this model, tells that group of duration ART treatment and sex group does not significantly influence the patients’ risk of death in this study.